The tools of mainstream psychiatry have saved lives. Lithium has prevented suicides. Clozapine has given people with treatment-resistant schizophrenia decades of functioning they would not otherwise have had. Antipsychotic medications, for all the controversy now surrounding them, have made it possible for people with severe psychotic illness to live outside institutions, to maintain relationships, to hold jobs. These are not small achievements. They are the product of decades of serious scientific work, and they deserve full acknowledgment from anyone who intends to say, as I intend to say, that the system built around these tools is operating well below its potential.

I have practiced psychiatry for nearly thirty years. In that time I have seen medication save people who would not have survived without it, and I have seen the same system fail people in ways that were entirely preventable. Both things are true. What follows is my honest attempt to hold both.

What the System Gets Right

Schizophrenia and bipolar I disorder are among the clearest examples of conditions where biological intervention is not supplementary but foundational. For a patient in acute psychosis, the clinical priority is stabilization, and antipsychotic medications accomplish this with an efficacy that few interventions in any medical specialty can match. The reduction in positive psychotic symptoms, hallucinations, delusions, disorganized thinking, that antipsychotics produce in the acute phase represents one of psychiatry’s genuine contributions to human welfare.

Mood stabilizers, particularly lithium, carry an evidence base that has held up across sixty years of clinical use. Lithium reduces the frequency and severity of manic episodes, and its anti-suicide effect in bipolar disorder is among the most robust findings in the psychiatric literature. Bipolar I disorder, untreated, carries a lifetime suicide risk that is twenty times the general population average. Lithium changes that. Valproate, lamotrigine, and the atypical antipsychotics now used as mood stabilizers have extended what is available to patients who don’t tolerate lithium or don’t respond to it adequately.

For the patients these medications are designed for, they are not a compromise or a shortcut. They are the treatment. A clinician who tells a patient with schizophrenia or bipolar I disorder that medication is unnecessary or optional is not offering a more enlightened form of care. They are putting that patient at serious risk. This is worth saying clearly, because the critique that follows is not aimed at these patients or at the interventions that keep them stable. It is aimed at what happens when a framework built for one population is applied to everyone.

The Non-Compliance Problem No One Discusses Honestly

Non-compliance with psychiatric medication is one of the most consequential and least honestly discussed failures in contemporary psychiatric care. In schizophrenia, non-compliance rates run between 40 and 60 percent across studies, depending on how compliance is defined and over what period it is measured. Among patients who discontinue antipsychotics after a first episode, relapse rates exceed 80 percent within two years.

What makes this clinically serious is that relapse in schizophrenia following medication discontinuation is not simply a return to baseline. Each psychotic episode is associated with progressive neurobiological changes, greater treatment resistance, longer time to recovery, and higher rates of incomplete remission. A patient who was fully stable on medication and discontinues it is not guaranteed to return to that level of stability when medication is restarted. Some never do. The interval between episodes, which tends to shorten with each successive relapse, matters. The number of episodes a person experiences over a lifetime matters. Non-compliance, in this context, is not a neutral choice. It carries a biological cost.

But here is what the honest accounting requires: non-compliance is rarely irrational, and treating it as irrational is how the system avoids examining its own contribution to the problem. The side effects of antipsychotic medications are real and serious. Weight gain, metabolic syndrome, sexual dysfunction, tardive dyskinesia, and the deeply distressing experience of emotional blunting or cognitive dulling are not minor inconveniences. They alter how a person inhabits their own body and life. Patients who stop taking medications because they feel worse on them than off them are not failing their treatment. They are communicating something the system has not created conditions to hear.

The therapeutic relationship, which is what determines whether a patient feels safe enough to say that a medication is making them feel like a stranger in their own life, is given insufficient time and institutional support in contemporary psychiatric practice. A fifteen-minute medication management appointment does not create conditions for that conversation. When non-compliance rises, the clinical question worth asking is not only what is wrong with the patient but what is wrong with the encounter.

Polypharmacy and Who Bears the Burden

The co-prescription of multiple psychiatric medications, often across multiple drug classes and without clear clinical rationale, has become standard practice in ways the evidence does not support. This problem is not evenly distributed across the population psychiatry serves.

Medicaid and Medicare populations, which skew heavily toward low-income patients and patients of color, face particular vulnerability. These programs historically require fewer prior authorizations for psychiatric medications than private insurance, which means there is less external check on prescribing complexity. The practical result is that the patients with the fewest resources and the least institutional power to question their treatment are receiving the most pharmacologically complex regimens. Studies examining Medicaid prescription data consistently document higher rates of antipsychotic polypharmacy, higher rates of benzodiazepine co-prescription, and higher average numbers of concurrent psychiatric medications compared to commercially insured populations.

The clinical rationale for many of these combinations is thin. The monitoring for drug interactions, cumulative metabolic burden, and long-term effects is often inadequate. This is not primarily a story about individual prescribers making poor decisions. It is a story about a system whose structure, including how it reimburses care and which populations it gives the least time to, produces predictable harms. Those harms fall most heavily on people who were already carrying the most.

The Antidepressant Question

The overuse of antidepressants in contemporary psychiatric and primary care practice is supported by the field’s own evidence, and saying so directly is not anti-psychiatry. It is reading the data.

The STAR*D study, the largest antidepressant effectiveness trial ever conducted, published in the American Journal of Psychiatry, found that only a third of patients achieved remission on their first medication trial. After four sequential treatment steps, cumulative remission reached approximately 67 percent, with high relapse rates among those who did remit. The study is frequently cited as evidence that antidepressants work. Read carefully, it is equally evidence of how often they are insufficient as a primary intervention, and how difficult sustained remission proves to be.

In 2022, a landmark umbrella review by Moncrieff and colleagues in Molecular Psychiatry examined the accumulated evidence for the serotonin hypothesis of depression and found it unsupported. The idea that depression is caused by a serotonin deficit, which has been the implicit rationale behind SSRI prescribing for three decades, does not hold up to the current evidence base. This does not mean antidepressants have no effect. It means the biological story told to justify their prescription may not be the story that explains whatever effect they do have, and the conditions under which they show meaningful benefit over placebo are considerably narrower than current prescribing patterns suggest.

The evidence for antidepressants is clearest in moderate to severe depression. For mild depression, the benefit over placebo is modest at best. A substantial portion of antidepressant prescribing in primary care and psychiatric settings falls outside the range where the evidence is strong. That prescribing is difficult to justify on clinical grounds, and its prevalence reflects not just individual clinical decisions but a system that offers medication more readily than it offers time.

A Framework Built for One Population, Applied to All

The limitations described so far are largely operational. They are problems of implementation, monitoring, and clinical culture that could theoretically be corrected within the existing model. The diagnostic biases in American psychiatry run deeper.

Black patients in the United States are diagnosed with schizophrenia at rates three to four times higher than white patients presenting with identical symptom profiles. This finding has been documented, challenged, and replicated consistently since the 1970s. It is not explained by actual differences in prevalence. It is explained by a diagnostic process that, operating without cultural context, reads hypervigilance, distrust of authority, and social withdrawal in a Black patient as evidence of psychotic process, rather than as a nervous system accurately calibrated to a genuinely threatening environment. The DSM has no category for appropriate threat perception. It has categories for deviations from a norm, and that norm was built on research populations that were overwhelmingly white, overwhelmingly Western, and overwhelmingly drawn from academic medical centers.

The consequences extend beyond individual misdiagnosis. The research that defines how schizophrenia presents, how it responds to treatment, and what outcomes look like was built on diagnosed populations that include people who may not have had the condition being studied. The treatment protocols derived from that research, the clinical training built on those protocols, the prescribing practices trained clinicians carry into their work, all of it is downstream of a compromised diagnostic foundation. A system that presents itself as empirically grounded is, in one of its most consequential domains, building on data it has never adequately examined for this bias.

This is the point at which the limitations of mainstream psychiatry stop being primarily about resource allocation or clinical culture and become a question about the validity of the framework itself.

An Incomplete Model

In 2022, Thomas Insel, who spent thirteen years as director of the National Institute of Mental Health overseeing approximately twenty billion dollars in research investment, assessed his own tenure with unusual candor. Despite the scale of investment in neuroscience and genetics, he wrote, he did not believe the field had moved the needle on morbidity and mortality. Suicide rates had not declined. Rates of disability from mental illness had not improved. The biological targets being pursued had not translated into better outcomes for the people the system was meant to serve.

This is not a fringe critique. It is a self-assessment from one of the most powerful figures in American psychiatric research. Allen Frances, who chaired the DSM-IV task force, made a related argument in his book Saving Normal, where he documented the diagnostic inflation that has steadily expanded psychiatric categories in ways that pathologize ordinary human suffering without improving care. These are insider voices. They are not calling for the dismantling of psychiatry. They are calling for honesty about what the current model can and cannot do.

Mainstream psychiatry is not a broken system. It is an incomplete one. It was built for a specific population, tested on a specific population, and calibrated to a specific set of assumptions about what mental illness is and where it comes from. Applied universally, to populations whose suffering has different roots, different expressions, and different needs, it helps some people substantially and misses others in ways that compound over years and decades. The populations being missed are not rare. They are not edge cases. They constitute, by any honest estimate, a significant proportion of everyone who walks through a psychiatric door.

The clinicians who feel this most acutely are often those who already know something is wrong. The psychiatrist who senses that a patient’s diagnosis doesn’t fit but has no alternative framework to offer. The therapist watching a client cycle through medication changes without addressing what is actually driving the suffering. The BIPOC clinician working inside a system whose diagnostic tools weren’t built for the patients in front of them. These clinicians are not failing. They are practicing at the edge of what the model allows them to see. What would it take to see further? That is the question this series will work through directly.

To see further requires acknowledging that mainstream psychiatry’s blind spots are not only clinical. They are structural. A framework calibrated to a narrow, historically privileged demographic will inevitably read the survival strategies of marginalized communities as pathology. Complex trauma, neurodivergence, and the chronic stress of navigating systemic racism do not remain in the mind. They produce measurable nervous system dysregulation that lives in the body. Resmaa Menakem’s work on racialized trauma, alongside decades of research into the social determinants of health, makes clear that mental health outcomes cannot be separated from poverty, housing instability, and structural violence. This series will work through these realities directly, examining what a root-cause approach to human suffering actually requires and what it would take to build one.

Dr. Yasin Choudry is a board-certified psychiatrist with nearly thirty years of clinical experience. His work focuses on the populations mainstream psychiatry consistently misses, including highly sensitive people, complex trauma survivors, neurodivergent adults, and those whose suffering has roots deeper than a diagnostic checklist can reach. He is the author of Radical Recovery: A Holistic Approach to Mental Health.

References and Further Reading

On the Efficacy of Antipsychotics and Mood Stabilizers

Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789–796.

Cipriani, A., Pretty, H., Hawton, K., & Geddes, J. R. (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials. American Journal of Psychiatry, 162(10), 1805–1819.

Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004). Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry, 161(2), 217–222.

On Non-Compliance and Relapse in Schizophrenia

Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. Journal of Clinical Psychiatry, 63(10), 892–909.

Weiden, P. J., & Olfson, M. (1995). Cost of relapse in schizophrenia. Schizophrenia Bulletin, 21(3), 419–429.

Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063–2071.

On Antidepressants: Efficacy, Overuse, and the Serotonin Hypothesis

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917.

Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry, 28(10), 3243–3256.

Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45.

Kirsch, I. (2010). The Emperor’s New Drugs: Exploding the Antidepressant Myth. Basic Books.

On Diagnostic Reliability and the Limits of the DSM

Regier, D. A., Narrow, W. E., Clarke, D. E., et al. (2013). DSM-5 field trials in the United States and Canada, Part II: Test-retest reliability of selected categorical diagnoses. American Journal of Psychiatry, 170(1), 59–70.

Frances, A. (2013). Saving Normal: An Insider’s Revolt Against Out-of-Control Psychiatric Diagnosis, DSM-5, Big Pharma, and the Medicalization of Ordinary Life. William Morrow.

British Psychological Society. (2018). The Power Threat Meaning Framework: Towards the Identification of Patterns in Emotional Distress, Unusual Experiences and Troubled or Troubling Behaviour, as an Alternative to Functional Psychiatric Diagnosis. British Psychological Society.

On Racial Disparities in Psychiatric Diagnosis

Gara, M. A., Minsky, S., Silverstein, S. M., Miskimen, T., & Strakowski, S. M. (2019). A naturalistic study of racial disparities in diagnoses at an outpatient behavioral health clinic. Psychiatric Services, 70(2), 130–134.

Schwartz, R. C., & Blankenship, D. M. (2014). Racial disparities in psychotic disorder diagnosis: A review of empirical literature. World Journal of Psychiatry, 4(4), 133–140.

Williams, D. R., & Mohammed, S. A. (2009). Discrimination and racial disparities in health: Evidence and needed research. Journal of Behavioral Medicine, 32(1), 20–47.

On Polypharmacy and Medicaid/Medicare Populations

Mojtabai, R., & Olfson, M. (2010). National trends in psychotropic medication polypharmacy in office-based psychiatry. Archives of General Psychiatry, 67(1), 26–36.

Verdoux, H., Tournier, M., & Bégaud, B. (2010). Antipsychotic prescribing trends: A review of pharmaco-epidemiological studies. Acta Psychiatrica Scandinavica, 121(1), 4–10.

On the Failure of Biological Psychiatry to Improve Outcomes

Insel, T. (2022). Healing: Our Path from Mental Illness to Mental Health. Penguin Press.

Stringaris, A. (2017). What is depression? Journal of Child Psychology and Psychiatry, 58(12), 1287–1289.

On Trauma, Adverse Childhood Experiences, and Complex PTSD

Felitti, V. J., Anda, R. F., Nordenberg, D., et al. (1998). Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: The Adverse Childhood Experiences (ACE) Study. American Journal of Preventive Medicine, 14(4), 245–258.

Herman, J. L. (1992). Trauma and Recovery: The Aftermath of Violence from Domestic Abuse to Political Terror. Basic Books.

Maercker, A., Brewin, C. R., Bryant, R. A., et al. (2013). Proposals for mental disorders specifically associated with stress: Cultural and international perspectives. The Lancet, 381(9878), 1683–1685.

van der Kolk, B. A. (2014). The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. Viking.

On High Sensitivity as a Neurobiological Trait

Aron, E. N., & Aron, A. (1997). Sensory-processing sensitivity and its relation to introversion and emotionality. Journal of Personality and Social Psychology, 73(2), 345–368.

Aron, E. N. (1996). The Highly Sensitive Person: How to Thrive When the World Overwhelms You. Broadway Books.

On Racialized Trauma and the Body

Menakem, R. (2017). My Grandmother’s Hands: Racialized Trauma and the Pathway to Mending Our Hearts and Bodies. Central Recovery Press.

On Social Determinants of Mental Health

World Health Organization Commission on Social Determinants of Health. (2008). Closing the Gap in a Generation: Health Equity through Action on the Social Determinants of Health. WHO Press.

Compton, M. T., & Shim, R. S. (Eds.). (2015). The Social Determinants of Mental Health. American Psychiatric Publishing.